Stryker CEO Lobo skeptical on 'repless' generic sales models (MassDevice)
Stryker CEO Kevin Lobo says he doesn't view the so-called 'repless' generic sales models piloted by orthopedic rivals Smith & Nephew and Wright Medical as a serious threat.
Stryker (NYSE:SYK) CEO Kevin Lobo is skeptical of so-called "repless" generic sales models for orthopedic procedures, he said today, even as rival (and potential acquisition) Smith & Nephew(FTSE:SN, NYSE:SNN) looks to expand its no-frills Syncera program.
Lobo, speaking at the J.P. Morgan Healthcare Conference in San Francisco, said that he's aware of programs like Syncera but doesn't see them as a credible threat.
"I look at a generic model very skeptically, regardless of which company is offering it," Lobo said. "Until these procedures are de-skilled it's very hard to imagine [not having] the salesforce and the services that we provide in the hospitals. If you don't have that, the operating rooms just don't flow effectively and efficiently. I don't know when they launched their initially but we are not seeing it in any meaningful way in the market."
Earlier this week Smith & Nephew CEO Olivier Bohoun touted his company's Sync...
